Literature DB >> 30894361

Atezolizumab Combo Approved for PD-L1-positive TNBC.

.   

Abstract

The FDA approved atezolizumab plus nab-paclitaxel for patients with locally advanced or metastatic triple-negative breast tumors expressing PD-L1. The combination is the first immunotherapy regimen to earn marketing authorization for any type of breast cancer. ©2019 American Association for Cancer Research.

Entities:  

Year:  2019        PMID： 30894361     DOI： 10.1158/2159-8290.CD-NB2019-038

Source DB:  PubMed          Journal:  Cancer Discov        ISSN： 2159-8274            Impact factor:   39.397


  15 in total

Review 1.  siRNA therapeutics for breast cancer: recent efforts in targeting metastasis, drug resistance, and immune evasion.

Authors:  Worapol Ngamcherdtrakul; Wassana Yantasee
Journal:  Transl Res       Date:  2019-08-19       Impact factor: 7.012

Review 2.  Emerging biomaterial-based strategies for personalized therapeutic in situ cancer vaccines.

Authors:  Dixita Ishani Viswanath; Hsuan-Chen Liu; David P Huston; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Biomaterials       Date:  2021-11-30       Impact factor: 12.479

3.  PD-L1 tumor-intrinsic signaling and its therapeutic implication in triple-negative breast cancer.

Authors:  Chunhua Chen; Shiheng Li; Junli Xue; Manlong Qi; Xin Liu; Yan Huang; Jinghua Hu; Haidong Dong; Kun Ling
Journal:  JCI Insight       Date:  2021-04-22

4.  Identification of a Triple Drug Combination That Is Synergistically Cytotoxic for Triple-Negative Breast Cancer Cells Using a Novel Combination Discovery Approach.

Authors:  Syed Ahmad; Qingping He; Kevin P Williams; John E Scott
Journal:  SLAS Discov       Date:  2020-05-22       Impact factor: 3.341

5.  Potentiating Antitumor Efficacy Through Radiation and Sustained Intratumoral Delivery of Anti-CD40 and Anti-PDL1.

Authors:  Hsuan-Chen Liu; Dixita I Viswanath; Federica Pesaresi; Yitian Xu; Licheng Zhang; Nicola Di Trani; Jesus Paez-Mayorga; Nathanael Hernandez; Yu Wang; Donald R Erm; Jeremy Ho; Antonia Susnjar; Xuewu Liu; Sandra Demaria; Shu-Hsia Chen; Bin S Teh; Edward Brian Butler; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Int J Radiat Oncol Biol Phys       Date:  2020-08-05       Impact factor: 8.013

6.  Engineered implantable vaccine platform for continuous antigen-specific immunomodulation.

Authors:  Dixita Ishani Viswanath; Hsuan-Chen Liu; Simone Capuani; Robin Shae Vander Pol; Shani Zakiya Saunders; Corrine Ying Xuan Chua; Alessandro Grattoni
Journal:  Biomaterials       Date:  2022-01-18       Impact factor: 15.304

Review 7.  Combining Diagnostic Imaging and Pathology for Improving Diagnosis and Prognosis of Cancer.

Authors:  Orazio Schillaci; Manuel Scimeca; Nicola Toschi; Rita Bonfiglio; Nicoletta Urbano; Elena Bonanno
Journal:  Contrast Media Mol Imaging       Date:  2019-07-01       Impact factor: 3.161

8.  Cluster of differentiation 8 and programmed cell death ligand 1 expression in triple-negative breast cancer combined with autosomal dominant polycystic kidney disease and tuberous sclerosis complex: a case report.

Authors:  Kenji Gonda; Takanori Akama; Takayuki Nakamura; Eiko Hashimoto; Naomi Kyoya; Yuichi Rokkaku; Yuko Maejima; Shoichiro Horita; Kazunoshin Tachibana; Noriko Abe; Tohru Ohtake; Kenju Shimomura; Koji Kono; Shigehira Saji; Seiichi Takenoshita; Eiji Higashihara
Journal:  J Med Case Rep       Date:  2019-12-24

9.  The small G-protein RalA promotes progression and metastasis of triple-negative breast cancer.

Authors:  Katie A Thies; Matthew W Cole; Rachel E Schafer; Jonathan M Spehar; Dillon S Richardson; Sarah A Steck; Manjusri Das; Arthur W Lian; Alo Ray; Reena Shakya; Sue E Knoblaugh; Cynthia D Timmers; Michael C Ostrowski; Arnab Chakravarti; Gina M Sizemore; Steven T Sizemore
Journal:  Breast Cancer Res       Date:  2021-06-12       Impact factor: 6.466

Review 10.  Adjuvant Effect of Toll-Like Receptor 9 Activation on Cancer Immunotherapy Using Checkpoint Blockade.

Authors:  Yu-Chen Chuang; Jen-Chih Tseng; Li-Rung Huang; Chun-Ming Huang; Chi-Ying F Huang; Tsung-Hsien Chuang
Journal:  Front Immunol       Date:  2020-05-29       Impact factor: 7.561
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.